Lung_Cancer_adaptive - Ethos

Launched by UNIVERSITY HOSPITAL, ESSEN · Jan 15, 2024

Keywords

ClinConnect Summary

This clinical trial, called Lung_Cancer_adaptive - Ethos, is studying a new way to deliver radiation therapy to patients with lung cancer. The goal is to see if an advanced treatment method called Adaptive Radiotherapy (ART) can improve the accuracy of radiation delivery compared to standard treatment techniques. In ART, doctors adjust the radiation plans based on how the tumor and surrounding tissues change from day to day, which may help reduce radiation exposure to healthy tissues while ensuring the tumor receives the right dose.

To be eligible for the trial, participants must be at least 18 years old and diagnosed with stage III or IV non-small cell lung cancer or small cell lung cancer. They need to be able to perform a specific breathing technique that helps with the treatment. During the trial, patients will receive radiation therapy over ten sessions, and doctors will carefully monitor how well the treatment is working and adjust it as needed. The study aims to find out how many patients can benefit from this new approach, making it an important step in improving lung cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with NSCLC/SCLC ≥18 years of age in stage III or IV, oligometastatic, for whom the indication for neoadjuvant or definitive radiotherapy/radiotherapy/chemotherapy has been established in the certified lung tumour board.
• Exclusion Criteria:
• • Patients who are unable to perform a reproducible breath-hold manoeuvre on inspiration are not included in this study.

Trial Officials